Conditions for dispensing from a pharmacy On prescription Manufacturer information Biomedica Foscama Industria Chimico Farmaceutica S.p.A., Ferentino, Italy Name, address and contact details (telephone, fax, e-mail) of the organization on the territory of the Republic of Kazakhstan that accepts complaints (suggestions) regarding the quality of medicinal products from consumers and is responsible for post-registration monitoring of the safety of the medicinal product Representative office of the closed joint stock company Claus Marsh Ltd in the Republic of Kazakhstan Almaty, 050012 Almaly district, Tole Bi street, 83 Trade name TAD 600 Dosage form, dosage Lyophilized powder for the preparation of solution for intravenous administration complete with solvent water for injection, 600 mg/4 ml Pharmacotherapeutic group Other drugs
This dual action is considered significant for maintaining balance between extracellular breakdown and renewal
Phase 2 trial results (48 weeks, adults with obesity): 1 mg dose: 7.2% body weight loss 4 mg dose: 12.9% body weight loss 8 mg dose: 17.3% body weight loss 12 mg dose: 24.2% body weight loss Placebo: 1.6% body weight loss Phase 3 TRIUMPH-4 results: 9 mg dose: 20.0% body weight loss (22.9 kg / 50.5 lbs) 12 mg dose: 23.7% body weight loss (27.2 kg / 60.0 lbs) Placebo: 4.6% body weight loss In a separate phase 3 analysis, retatrutide at the highest dose achieved up to 28.7% weight loss
These substances can disrupt the central nervous systems signals, affecting a persons mood, memory, willpower, pain sensations, learning functions and perceptions of self and surroundings
Brizuela L, Richardson A, Marsischky G, Labaer J (2002) The FLEXGene repository: exploiting the fruits of the genome projects by creating a needed resource to face the challenges of the post- genomic era
Nature.com